Shionogi Files Early NDA For Flu Drug Peramivir, Aims For 3 Million User Annual Supply
This article was originally published in PharmAsia News
Executive Summary
Shionogi announced Nov. 4 the company filed a new drug application for influenza drug peramivir with Japan's Ministry of Health, Labor and Welfare in October. The early NDA submission came just three month after the Osaka-based company completed a Phase III study for the drug
You may also be interested in...
Korea's Green Cross Seeks To Unveil Injectable Flu Antiviral Peramivir Even Before KFDA Approval
SEOUL - With or without an approval from Korea FDA, South Korea's vaccine producer Green Cross is gearing up to launch its version of injectable antiviral peramivir, which was developed by BioCryst Pharmaceuticals for treatment of influenza
Korea's Green Cross Seeks To Unveil Injectable Flu Antiviral Peramivir Even Before KFDA Approval
SEOUL - With or without an approval from Korea FDA, South Korea's vaccine producer Green Cross is gearing up to launch its version of injectable antiviral peramivir, which was developed by BioCryst Pharmaceuticals for treatment of influenza
Shionogi Pushes For Fast-Track Approval Of Flu Treatment Peramivir
TOKYO - Shionogi announced Sept. 30 it is preparing to submit an application for approval for influenza treatment peramivir for A/H1N1 and other varieties of flu